EFHD2 contributes to non-small cell lung cancer cisplatin resistance by the activation of NOX4-ROS-ABCC1 axis

EFHD2 contributes to non-small cell lung cancer cisplatin resistance by the activation of NOX4-ROS-ABCC1 axis

Recurrence and metastasis remain the major cause of cancer mortality. Even for early-stage lung cancer, adjuvant chemotherapy yields merely slight increase to patient survival. EF-hand domain-containing protein D2 (EFHD2) has recently been implicated in recurrence of patients with stage I lung adeno...

Full description

Bibliographic Details
Main Authors: Chi-Chen Fan, Sheng-Ta Tsai, Chen-Yuan Lin, Ling-Chu Chang, Juan-Cheng Yang, Guan‐Yu Chen, Yuh-Pyng Sher, Shao-Chun Wang, Michael Hsiao, Wei‐Chao Chang
Format: Article
Language:English
Published: Elsevier 2020-07-01
Series:Redox Biology
Subjects:
EFHD2
Recurrence
Adjuvant chemotherapy
NOX4
ABCC1
Ibuprofen
Online Access:http://www.sciencedirect.com/science/article/pii/S2213231720303785

Internet

http://www.sciencedirect.com/science/article/pii/S2213231720303785

Similar Items